Oks Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 04-07-2024
- Paid Up Capital ₹ 0.10 M
as on 04-07-2024
- Company Age 20 Year, 3 Days
- Last Filing with ROC 31 Mar 2023
- Revenue 216.41%
(FY 2022)
- Profit 208.47%
(FY 2022)
- Ebitda 86.64%
(FY 2022)
- Net Worth 3.15%
(FY 2022)
- Total Assets 1.84%
(FY 2022)
About Oks Biotech
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Seher Nayeem, Nizamuddin Khan, and Nitin Talwar serve as directors at the Company.
- CIN/LLPIN
U74999DL2004PTC131332
- Company No.
131332
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Dec 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Oks Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Seher Nayeem  | Director | 31-Aug-2021 | Current |
Nitin Talwar  | Additional Director | Current | |
| Nizamuddin Khan | Director | 31-Mar-2023 | Current |
Financial Performance and Corporate Structure Insights of Oks Biotech.
Oks Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 216.41% increase. The company also saw a substantial improvement in profitability, with a 208.47% increase in profit. The company's net worth moved up by a moderate rise of 3.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oks Biotech?
In 2020, Oks Biotech had a promoter holding of 99.99% and a public holding of 0.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Exactus Corporation Private LimitedActive 32 years 8 monthsSeher Nayeem and Nizamuddin Khan are mutual person
Oks Group International Private LimitedActive 20 years 7 monthsSeher Nayeem, Nizamuddin Khan and 1 more are mutual person
- Oks Education Private LimitedActive 12 years 3 months
Seher Nayeem, Nizamuddin Khan and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Oks Biotech?
Unlock and access historical data on people associated with Oks Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oks Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oks Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
